April 5, 2017—Neither the expansion of the 340B drug discount program made by the Affordable Care Act nor changes in Medicare Part B drug reimbursement policy are primary causes of the recent wave of private oncology practice consolidations with hospitals, says a new study in Health Affairs. Instead, the vertical amalgamation likely is part of a broader trend toward integrated healthcare.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)